- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 473/32 - Nitrogen atom
Patent holdings for IPC class C07D 473/32
Total number of patents in this class: 249
10-year publication summary
18
|
20
|
19
|
17
|
9
|
28
|
12
|
20
|
10
|
7
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Signal Pharmaceuticals, LLC | 179 |
20 |
Boehringer Ingelheim International GmbH | 4695 |
8 |
Celgene Corporation | 1412 |
8 |
Chengdu Baiyu Pharmaceutical Co., Ltd. | 69 |
6 |
Board of Regents, The University of Texas System | 5772 |
5 |
Takeda Pharmaceutical Company Limited | 2711 |
5 |
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | 187 |
5 |
Neupharma, Inc. | 72 |
5 |
Pharmacopeia, Inc. | 19 |
5 |
S*BIO Pte Ltd. | 25 |
5 |
AstraZeneca AB | 2917 |
4 |
Cancer Research Technology Limited | 520 |
4 |
Incyte Holdings Corporation | 654 |
4 |
Research Triangle Institute | 408 |
4 |
Kangbaida (Sichuan) Biotechnology Co., Ltd. | 17 |
4 |
F. Hoffmann-La Roche AG | 7929 |
3 |
The Regents of the University of California | 19868 |
3 |
Wyeth LLC | 652 |
3 |
Purdue Research Foundation | 3583 |
3 |
Ildong Pharmaceutical Co., Ltd. | 94 |
3 |
Other owners | 142 |